Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.

MS, Sulkowski; DF, Gardiner; M, Rodriguez-Torres; KR, Reddy; T, Hassanein; I, Jacobson; E, Lawitz; AS, Lok; F, Hinestrosa; PJ, Thuluvath; H, Schwartz; DR, Nelson; GT, Everson; T, Eley; M, Wind-Rotolo; SP, Huang; M, Gao; D, Hernandez; F, McPhee; D, Sherman; R, Hindes; W, Symonds; C, Pasquinelli; DM, Grasela

doi:10.1056/nejmoa1306218

Public

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.

Shared by NobleBlocks on Jan 1, 2014 • 12:00 AM UTC

Authors:

Sulkowski MS

Gardiner DF

Rodriguez-Torres M

Abstract

<h4>Background</h4>All-oral combination therapy is desirable for patients with chronic hepatitis C virus (HCV) infection. We evaluated daclatasvir (an HCV NS5A replication complex inhibitor) plus sofosbuvir (a nucleotide analogue HCV NS5B polymerase inhibitor) in patients infected with HCV genotype ...

Discussions